Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.55 |
| ▸ | DRD2 | P14416 | 5/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4756371 | 0.86 | DRD2 (0.43) | GPR119DRD2CHRM4CCR1 | |
| SCHEMBL4505015 | 0.85 | GPR119 (0.60) | GPR119 | |
| SCHEMBL28774952 | 0.84 | DRD2 (0.46) | GPR119DRD2CHRM4BACE1KDM1A | |
| SCHEMBL4513559 | 0.82 | GPR119 (0.70) | GPR119CHRM4KDM4EPKM | |
| SCHEMBL6011556 | 0.77 | GPR119 (0.62) | GPR119KDM4EPKM | |
| SCHEMBL4502678 | 0.77 | GPR119 (0.60) | GPR119KDM4EPKM | |
| SCHEMBL1576199 | 0.77 | GPR119 (0.61) | GPR119KDM4EPKM | |
| SCHEMBL1575603 | 0.76 | GPR119 (0.63) | GPR119 | |
| SCHEMBL1575007 | 0.75 | GPR119 (0.64) | GPR119 | |
| SCHEMBL1575604 | 0.75 | GPR119 (0.71) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | GPR119, GCGR, GPBAR1 | GPR119 1/4885DRD2 1031/4885CHRM4 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.